H⁺/K⁺-ATPase inhibitors: a patent review

Bibliography

• Kone B, Renal H. K-ATPase: structure, function and regulation. Miner Electrolyte Metab 1996;22:349
   PubMedGoogle Scholar
• Bamford M. 3 H+/K+ ATPase inhibitors in the treatment of acid-related disorders. Prog Med Chem 2009;47:75–162
   Google Scholar
• Karimian K, Tam TF, Leung-Toung RCSH, Thiadiazole compounds useful as inhibitors of H+/K+ ATPase. US6060472; 2000
   Google Scholar
• Gant TG, Sarshar S. Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties. US7598273B2; 2009
   Google Scholar
• Lindberg P, Pias-Mass J, Serra-Carreras J, Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps. US6380222B2; 2002
   Google Scholar
• Lindberg P, Pinas-Masso J, Serra-Carreras J, Use of an H+, K+-ATPase inhibitor in the treatment of asthma. US20030216439A1; 2003
   Google Scholar
• Lindberg P, Pinas-Masso J, Serra-Carreras J, Use of an H+, K+-ATPase inhibitor in the treatment of asthma. US20060025450A1; 2006
   Google Scholar
• Lindberg P, Pias-Mass J, Serra-Carreras J, Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome. US6599927B2; 2003
   Google Scholar
• Moorman AE, Becker DP, Flynn DL. Method of using (H+/K+) ATPase inhibitors as antiviral agents. US6906078B2; 2005
   Google Scholar
• Moormann AE, Becker DP, Flynn DL, Method of using (H+/K+) ATPase inhibitors as antiviral agents. US5945425; 1999
   Google Scholar
• Wang HYL, O'Doherty GA. Modulators of Na/K-ATPase: a patent review. Expert Opin Ther Pat 2012;22(6):587-605
   PubMed Web of Science ®Google Scholar
• Shin JM, Sachs G. Dimerization of the gastric H, K-ATPase. J Biol Chem 1996;271:1904
   PubMedGoogle Scholar
• Caplan MJ. The future of the pump. J Clin Gastroenterol 2007;41:S217
   Web of Science ®Google Scholar
• Sachs G, Shin JM, Vagin O, The gastric H, K ATPase as a drug target: past, present, and future. J Clin Gastroenterol 2007;41:S226
   PubMed Web of Science ®Google Scholar
• Sachs G, Shin J, Munson K, The control of gastric acid and Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;14:1383
   PubMed Web of Science ®Google Scholar
• Sachs G, Shin J, Howden C. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 2006;23:2
   PubMed Web of Science ®Google Scholar
• Ruwart M, Nezamis J, Rush B, Timoprazole is a unique cytoprotective agent in the rat. Digestion 1984;30:33
   PubMed Web of Science ®Google Scholar
• Zhang ML, Sugawa H, Mori T. Inhibition of thyrocyte iodide uptake by H+ K+ ATPase inhibitor, timoprazole. Endocr J 1995;42:489
   PubMed Web of Science ®Google Scholar
• Bohlin M, Horvath K. Crystalline form of the S-enantiomer of omeprazole. US6162816; 2000
   Google Scholar
• Von Unge S. Process for preparing pure salts of pyridinylmethyl-sulfinyl-1H-benzimidazole. US5693818; 1997
   Google Scholar
• Cotton H, Kronstrm A, Mattson A, Form of S-omeprazole. US7411070; 2002
   Google Scholar
• Nilsson M. Potassium salt of (s)-omeprazole. US6511996; 2003
   Google Scholar
• Jiang S, Meadows J, Anderson SA, Antileishmanial activity of the antiulcer agent omeprazole. Antimicrob Agents Chemother 2002;46:2569
   PubMed Web of Science ®Google Scholar
• Kuipers E, Nelis G, Klinkenberg-Knol E, Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004;53:12
   PubMed Web of Science ®Google Scholar
• Li X, Ge Z, Chen X, Duodenal gastric metaplasia and Helicobacter pylori infection in patients with diffuse nodular duodenitis. Braz J Med Biol Res 2007;40:897
   PubMed Web of Science ®Google Scholar
• Laine L, Hunt R, El-Zimaity H, Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003;98:562
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Johanson JF, Suchower LJ, Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial. Am J Gastroenterol 2005;100:2650
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Hermida C, Pajares JM. Are twelve days of omeprazole, amoxicillin and clarithromycin better than six days for treating H. pylori infection in peptic ulcer and in non-ulcer dyspepsia? Hepatogastroenterology 2001;48:1383
   PubMed Web of Science ®Google Scholar
• Fock K, Teo E, Ang T, Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia. World J Gastroenterol 2005;11:3091
   PubMed Web of Science ®Google Scholar
• Jensen RT. Consequences of long term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 2006;98:4
   PubMed Web of Science ®Google Scholar
• Macintire DK, Drobatz KJ, Haskins SC. Manual of small animal emergency and critical care medicine. Wiley-Blackwell; 2005 (Book)
   Google Scholar
• Lau JY, Leung WK, Wu JCY, Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med 2007;356:1631
   PubMed Web of Science ®Google Scholar
• Harty RF, Ancha HB. Stress ulcer bleeding. Curr Treat Options Gastroenterol 2006;9:157
   PubMedGoogle Scholar
• Malfertheiner P, Megraud F, O'Morain CA, Management of Helicobacter pylori infection – the Maastricht IV/Florence consensus report. Gut 2012;61:646
   PubMed Web of Science ®Google Scholar
• Nohara A, Maki Y. Pyridine derivatives and their production. EP0174726; 1989
   Google Scholar
• Kato M, Toyoshima Y, Iwano N. Production of 2-(2-Pyridylmethylsulfinyl)-benzimidazole compounds. EP0302720; 1992
   Google Scholar
• Avrutov I, Mendelovici M. Processes for the production of substituted 2-(2-Pyridylmethyl) sulfinyl-1H- benzimidazoles. WO2002062786; 2002
   Google Scholar
• Finkelstein N. Preparation Of Lansoprazole And Related Compounds. WO2004011455; 2004
   Google Scholar
• Tsujii M, Niikawa N, Takayanagi K, Sulfoxide compounds and acetone complexes, and a process for producing the same. US6180652; 2001
   Google Scholar
• Kato M, Toyoshima Y, Iwano N. Production of 2-(2-pyridylmethylsulfinyl) benzimidazole compounds by selective oxidation in the presence of a vanadium catalyst. US5578732; 1996
   Google Scholar
• Kato M, Ishida T. Crystals of benzimidazole derivatives and their production. US6002011; 1999
   Google Scholar
• Singer C, Liberman A, Veinberg I, Method for the purification of lansoprazole. US6909004; 2005
   Google Scholar
• Singer C, Liberman A, Veinberg I, Method for the purification of lansoprazole. US7022859; 2006
   Google Scholar
• Singer C, Liberman A, Veinberg I, Method for the purification of lansoprazole. US7622588; 2009
   Google Scholar
• Sugano K, Kontani T, Katsuo S, Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol 2012;47(5):540-52
   PubMed Web of Science ®Google Scholar
• Lee SH, Jang BI, Jeon SW, A multicenter, randomized, comparative study to determine the appropriate dose of lansoprazole for use in the diagnostic test for gastroesophageal reflux disease. Gut Liver 2011;5:302
   PubMed Web of Science ®Google Scholar
• Vergara M, Vallve M, Gisbert J, Meta analysis: comparative efficacy of different proton pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;18:647
   PubMed Web of Science ®Google Scholar
• Gisbert JP. Potent gastric acid inhibition in Helicobacter pylori eradication. Drugs 2005;65:83
   PubMed Web of Science ®Google Scholar
• Holbrook JT, Wise RA, Gold BD, Lansoprazole for children with poorly controlled asthma. JAMA 2012;307:373
   PubMed Web of Science ®Google Scholar
• Wilcox CM, Seay T, Arcury J, Presentation, response to lansoprazole therapy, and outcome of Zollinger-Ellison syndrome-like gastric acid hypersecretors. Scand J Gastroenterol 2011;46:277
   PubMed Web of Science ®Google Scholar
• Spugnini EP, Baldi A, Buglioni S, Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med 2011;9:221
   PubMed Web of Science ®Google Scholar
• Barradell L, Faulds D, McTavish D. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992;44:225
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Sanaka M, Anjiki H, No relationship between plasma desacyl-ghrelin levels and rabeprazole-related delay in gastric emptying: controlled study in healthy volunteers. Drugs R&D 2008;9:345
   PubMed Web of Science ®Google Scholar
• McNicholl A, Linares P, Nyssen O, Meta analysis: esomeprazole or rabeprazole vs. first generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012;36(5):414-25
   PubMed Web of Science ®Google Scholar
• Souda S, Ueda N, Miyazawa S, Pyridine derivatives having anti-ulcerative activity. US5998445; 1999
   Google Scholar
• Venkatraman S, Reddy MS, Eswaraiah S, Crystalline form Z of rabeprazole sodium and process for preparation thereof. US20040180935A1; 2004
   Google Scholar
• Miwa H, Sasaki M, Furuta T, Efficacy of rabeprazole on heartburn symptom resolution in patients with non erosive and erosive gastro‐oesophageal reflux disease: a multicenter study from Japan. Aliment Pharmacol Ther 2007;26:69
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, Gingras MH, Bardram L, The Zollinger-Ellison syndrome and mismeasurement of gastrin. Gastroenterology 2011;140(5):1444-53
   PubMed Web of Science ®Google Scholar
• Jungnickel PW. Pantoprazole: a new proton pump inhibitor. Clin Ther 2000;22:1268
   PubMed Web of Science ®Google Scholar
• Das SK, Roy C. The protective role of aegle marmelos on aspirin–induced gastro-duodenal ulceration in albino rat model: a possible involvement of antioxidants. Saudi J Gastroenterol 2012;18:188
   PubMed Web of Science ®Google Scholar
• Liang CM, Lee JH, Kuo YH, Intravenous non-high-dose pantoprazole is equally effective as high-dose pantoprazole in preventing rebleeding among low risk patients with a bleeding peptic ulcer after initial endoscopic hemostasis. BMC Gastroenterol 2012;12:28
   PubMed Web of Science ®Google Scholar
• Wu JCY, Sung JJY. Pharmacologic therapy for nonvariceal upper gastrointestinal bleeding. Gastrointest Endosc Clin N Am 2011;21(4):671-9
   PubMedGoogle Scholar
• Gisbert JP, Khorrami S, Calvet X, Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2004;16:89
   PubMed Web of Science ®Google Scholar
• Ward RM, Kearns GL, Tammara B, A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease. J Clin Pharmacol 2011;51:876
   PubMed Web of Science ®Google Scholar
• Brunner G, Athmann C, Schneider A. Long term, open label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid peptic disease. Aliment Pharmacol Ther 2012;36(1):37-47
   PubMed Web of Science ®Google Scholar
• Sripathi S, Bojja RR, Karnati VR, An improved synthesis of antiulcerative drug: tenatoprazole. Org Process Res Dev 2008;13:804
   Web of Science ®Google Scholar
• Matsuishi N, Takeda H, Iizumi K, Imidazo [4, 5-b] pyridine compounds, process for preparing same and pharmaceutical compositions containing same. EP0254588; 1992
   Google Scholar
• Galmiche J, Bruley Des Varannes S, Ducrotte P, Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther 2004;19:655
   PubMed Web of Science ®Google Scholar
• Shin JM, Cho YM, Sachs G. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J Am Chem Soc 2004;126:7800
   PubMed Web of Science ®Google Scholar
• Hunt RH, Armstrong D, James C, Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol 2005;100:1949
   PubMed Web of Science ®Google Scholar
• Shin JM, Sachs G. Restoration of acid secretion following treatment with proton pump inhibitors. Gastroenterology 2002;123:1588
   PubMed Web of Science ®Google Scholar
• Piche T, Galmiche JP. Pharmacological targets in gastrooesophageal reflux disease. Basic Clin Pharmacol Toxicol 2005;97:333
   PubMed Web of Science ®Google Scholar
• Schutze F. Use of tenatoprazole for the treatment of gastroesophageal reflux disease. US20110152314; 2011
   Google Scholar
• Dai L, Fan D, Wang X, Improved synthetic approach to tenatoprazole. Synth Commun 2008;38:576
   Web of Science ®Google Scholar
• Schutze F, Charbit S, Ficheux H, Pharmaceutical composition combining tenatoprazole and an anti-inflammatory agent. US20100048518; 2009
   Google Scholar
• Wallmark B, Briving C, Fryklund J, Inhibition of gastric H+, K+- ATPase and acid secretion by SCH 28080, a substituted pyridyl (1, 2a) imidazole. J Biol Chem 1987;262:2077
   PubMed Web of Science ®Google Scholar
• Lee KKC. Discontinued drugs in 2005: pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs. Expert Opin Investig Drugs 2006;Dec15(12):1497-505
   PubMed Web of Science ®Google Scholar
• Bailey N, Bamford MJ, Brissy D, Orally active C-6 heteroaryl-and heterocyclyl-substituted imidazo [1, 2-a] pyridine acid pump antagonists (APAs). Bioorg Med Chem Lett 2009;19:3602
   PubMed Web of Science ®Google Scholar
• Plachetka JR. Dosage form for treating gastrointestinal disorders. US20060165797Al; 2006
   Google Scholar
• Pettersson A, Nystrom C, Hakansson Y. Gastric Acid Secretion Inhibiting Composition. US20120121664; 2012
   Google Scholar
• Horn J. The proton-pump inhibitors: similarities and differences. Clin Ther 2000;22:266
   PubMed Web of Science ®Google Scholar
• Bergman MP, Amedei A, D'Elios MM, Characterization of H+, K+-ATPase T cell epitopes in human autoimmune gastritis. Eur J Immunol 2003;33:539
   PubMed Web of Science ®Google Scholar
• Choi WH, Park DI, Oh SJ, Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea. Korean J Gastroenterol 2008;51:280
   PubMedGoogle Scholar
• Niazi M, Silberg DG, Miller F, Evaluation of the pharmacokinetic interaction between lesogaberan (AZD3355) and esomeprazole in healthy subjects. Drugs R D 2010;10:243
   PubMedGoogle Scholar
• Lund VJ. Fortnightly review: diagnosis and treatment of nasal polyps. BMJ 1995;311:1411
   PubMedGoogle Scholar
• Juergens U. Use of a non- steroidal anti- inflammatory drug for topical and systemic treatment of acute and chronic polypoid rhinosinusitis. WO1997003659; 1997
   Google Scholar
• Murphy KR, Uryniak T, Martin UJ, The effect of budesonide/formoterol pressurized metered-dose inhaler on predefined criteria for worsening asthma in four different patient populations with asthma. Drugs R D 2012;12:9
   PubMedGoogle Scholar
• Zelina S, Sheen CW, Radzio J, Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 reverse transcriptase facilitates dual resistance to zidovudine and lamivudine. Antimicrob Agents Chemother 2008;52:157
   PubMed Web of Science ®Google Scholar
• Simon MW, Fish DN, Deeter RG. Pharmacokinetics and safety of valaciclovir in children with epstein-barr virus illness. Drugs R D 2002;3:365
   PubMedGoogle Scholar
• Longo DL, Kasper DL, Jameson JL, Antiviral drugs active against herpesvirus infections. Harrison's™ principles of internal medicine. 18th edition. McGraw-Hill; 2012
   Google Scholar
• Chisholm C, Lopez L. Cutaneous infections caused by herpesviridae: a review. Arch Pathol Lab Med 2011;135:1357
   PubMed Web of Science ®Google Scholar
• Shahian T, Lee GM, Lazic A, Inhibition of a viral enzyme by a small-molecule dimer disruptor. Nat Chem Biol 2009;5:640
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang H, Meng L, Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers. Eur J Clin Pharmacol 2010;66:563
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang P, Jiang N, Influence of Cytochrome P450 2C19 on the pharmacokinetics of lansoprazole administered by single and successive intravenous infusion in healthy Chinese volunteers. Drugs Ther Stud 2012;2:e3
   Google Scholar
• Wang Y, Zhang H, Meng L, The pharmacokinetics and bioavailability of rabeprazole following single intravenous infusion and oral administration in healthy Chinese volunteers. Drugs Ther Stud 2011;2:3
   Google Scholar
• Wang Y, Wu C, Zhang J, Investigation of bioaVailability and bioequivalence of pantoprazole enteric- coated Capsules. China Pharm 2009;18:3
   Google Scholar
• Wang Y, Yuan Y, Meng L, Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. Eur J Clin Pharmacol 2011;67:25
   PubMed Web of Science ®Google Scholar
• de Argila CM. Safety of potent gastric acid inhibition. Drugs 2005;65:97
   PubMed Web of Science ®Google Scholar
• Esplugues JV. A pharmacological approach to gastric acid inhibition. Drugs 2005;65:7
   PubMed Web of Science ®Google Scholar
• Simon WA, Herrmann M, Klein T, Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther 2007;321:866
   PubMed Web of Science ®Google Scholar